切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2014, Vol. 02 ›› Issue (03) : 11 -15. doi: 10.3877/cma.j.issn.2095-5782.2014.03.004

所属专题: 文献

肿瘤介入

经导管动脉化疗栓塞术联合经皮125I粒子植入序贯治疗肝癌伴门静脉主干癌栓
黄宁1, 杨维竹1,(), 江娜1, 郑曲彬1, 黄兢姚1   
  1. 1. 350001 福州,福建医科大学附属协和医院介入科
  • 收稿日期:2013-07-04 出版日期:2014-08-01
  • 通信作者: 杨维竹

Treatment of liver cancer complicated by MPVTT through TACE combined with percutaneous 125I seed implantation sequential

Ning Huang1, Weizhu Yang1(), Na Jiang1, Qubin Zheng1, Jingyao Huang1   

  1. 1. Department of Interventional Radiology, Affiliated Union Hospital of Fujian Medical University, Fuzhou 350001, China
  • Received:2013-07-04 Published:2014-08-01
  • Corresponding author: Weizhu Yang
引用本文:

黄宁, 杨维竹, 江娜, 郑曲彬, 黄兢姚. 经导管动脉化疗栓塞术联合经皮125I粒子植入序贯治疗肝癌伴门静脉主干癌栓[J/OL]. 中华介入放射学电子杂志, 2014, 02(03): 11-15.

Ning Huang, Weizhu Yang, Na Jiang, Qubin Zheng, Jingyao Huang. Treatment of liver cancer complicated by MPVTT through TACE combined with percutaneous 125I seed implantation sequential[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2014, 02(03): 11-15.

目的

评价经导管动脉化疗栓塞术(TACE)联合经皮125I放射性粒子植入序贯治疗肝癌伴门脉主干瘤栓的临床疗效及安全性。

方法

2010年1月至2012年3月48例确诊为肝癌合并门静脉主干癌栓患者,TACE术后1周进行经皮门脉瘤栓125I放射性粒子植入序贯治疗。随访时间12-24月,对比序贯治疗前后各项临床指标、影像学的变化,以评价其疗效及安全性。

结果

48例患者共接受215次TACE治疗,平均每例患者4.5次,每例患者平均植入粒子数16枚,技术成功率100%,全组未出现治疗相关性死亡,肝内病灶客现缓解率为37.3%(18/48)。瘤栓3个月后影像复查平均回缩3.9mm,完全缓解(CR)15例,部分缓解(PR)25例,稳定(SD)6例,进展(PD)2例,总有效率(CR+PR)为83.3%。门脉主干内径恢复大于80%共41例(85.4%)。1年生存率和2年生存率分别为47.9%,33.33%,中位生存时间为15.8月。48例患者术后3个月患者的肝功能、血常规与术时比较,P=0.028,差异均无统计学意义。

结论

TACE联合经皮125I放射性粒子植入序贯治疗原发性肝癌伴门静脉主干癌栓是一种有效安全的方法。

Objective

To evaluate the clinical therapeutic effect and safety of treatment of liver cancer complicated by main portal vein tumor thrombus (MPVTT) through transcatheter arterial chemoembolization (TACE) combined with percutaneous 125I radioactive seeds implantation sequential.

Methods

Among patients with liver cancer complicated by PVTT who were given interventional therapy at our hospital, 48 of them were diagnosed as liver cancer complicated by MPVTT and given percutaneous 125I radioactive seeds implantation sequential for portal vein tumor thrombus within one week after TACE operation. During the follow-up visit for 12-24 months, the changes of various clinical indicators and iconography before and after sequential therapy were compared to evaluate its therapeutic effect and safety.

Results

48 Patients have been given totally 215 TACE therapies, 4.5 therapies for each patient in average, and 16 seeds were implanted into each patient in average, with the technical success rate of 100%. The treatment-related death did not occur in the whole group, and the objective remission rate of intrahepatic focal was 37.3% (18/48). The tumor thrombus averagely retracted by 3.9mm in imaging recheck after 3 months. 15 patients were with complete remission (CR), 25 patients with partial remission (PR), 6 patients with stable disease (SD), and 2 patients with progressive disease (PD), and the total remission rate (CR+PR) was 83.3%. 41 patients (85.4%) had portal vein trunk inner diameter recovered for above 80%. The 1-year and 2-year survival rate was respectively 47.9% and 33.33%, and the median survival time was (15.8±3.8) months. Compare the liver function and blood routine test results of 48 patients 3 months after operation with those during operation, P=0.028, and all the differences showed no statistical significance.

Conclusion

Treatment of liver cancer complicated by main portal vein tumor thrombus (MPVTT) through transarterial chemoembolization (TACE) combined with percutaneous 125I radioactive seeds implantation sequential is safety and effective.

1
Villa E,MoIes A,Ferretti I, et a1. Natural history of inoperable hepatocellular carcinoma;estrogen receptors’status in the tumor is the strongest prognostic factor for survival[J]. Hepatology, 2000, 32(2): 233-238.
2
Itamoto T,Nakahara H,Tashiro H,et a1. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein[J]. J Stag Oncol, 2002, 80(3): 143-148.
3
Yanmaki T,Kurokawa F,Shirahashi H, et a1. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma[J]. Hepatol Res, 2002, 23(1): 7-17.
4
Ohkubo T,Yamamoto J,Sugawara Y, et al. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis[J]. J Am Coll Surg, 2000, 191(6): 657-660.
5
Llovet JM,Bru C,Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification[J]. Semin Liver Dis, 1999, 19(3): 329-338.
6
Llovet JM. Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma[J]. J Natl Cancer Inst, 2008, 100(10): 698-711.
7
程树群,吴孟超,陈汉,等.肝癌门静脉癌栓分型的影像学意义[J].中华普通外科杂志, 2004, 19(4):200-201.
8
程树群,吴孟超,程红岩,等.原发性肝癌门静脉癌栓生长特征的研究[J].中国现代普通外科进展,2003,6(2):103-105.
9
Kim, JY,Yoo, EJ,Jang, JW, et al. Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Radiat Oncol, 2013, 16(8): 15.
10
Kim JY,Chung SM,Choi BO, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy[J]. Hepatol Res, 2011,41(9):813-824.
11
Oh D,Lim do H.Park, HC, et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity.[J] Am J Clin Oncol, 2010, 33(4):370-375.
12
Yamada K,Izaki K,Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 57(1):113-119.
13
Le Treut YP,Hardwigsen J,Ananian P. et al., Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series[J]. J Gastrointest Surg, 2006, 10(6):855-862.
14
Yamakado K,Tanaka N,Nakatsuka A, et a1. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein[J]. J Hepatol, 1999, 30(4): 660-668.
15
龚高全,王小林,周康荣, 等. 肝癌伴门静脉癌栓的金属内支架治疗的初步研究[J]. 临床放射学杂志, 2003, 22(1): 498-500.
16
Yamada K,Lzaki K,Sugimoto K, et a1. Prospective trial of combined trancatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 57(1): 113-119.
17
Nakagawa K,Yamashita H,Shiraishi K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2005,11(46): 7237-7241.
18
Nag S,DeHaan M. Long-term follow-up of patients of intrahepatic malignancies treated with iodine一125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2006, 64(3): 736-744.
19
Zhang FJ,Li CX,Jiao DC, et a1. CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma[J]. Chin Med J, 2008, 121(23): 2410-2414.
20
李说,颜志平,张雯, 等. 兔门静脉主干内植入连续排列125I粒子条的实验研究[J].介入放射学杂志, 2009, 18(8): 607-611.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[5] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[6] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[7] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[8] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[9] 林小勇, 张兰霞, 曾庆劲, 贺需旗, 谭雷, 郭光辉, 龙颖琳, 李凯, 吴宇轩. 负压抽吸活检针在肝困难病灶活检中的初步应用研究[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 694-698.
[10] 雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
[11] 欧阳佳裕, 李刚, 贺露瑶, 罗娜. 双层探测器光谱CT在早期原发性肝癌中的诊断价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 557-561.
[12] 陈志坚, 俞建达, 池小斌, 吕立志, 陈永标. 三维可视化技术在腹腔镜肝巨大肿瘤切除中的应用价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 302-307.
[13] 黄俊豪, 陈宗杰, 胡添松. 血小板相关参数对肝内胆管细胞癌根治性切除患者预后预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 308-312.
[14] 马欢欢, 马晨辉, 邓小博, 王博方, 何普毅, 王云鹏, 许博, 俞荣, 王娜, 陈昊. 肝癌实体瘤治疗疗效评价系统的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 377-383.
[15] 王凯飞, 牟怡平, 李晓辉, 王瑞涛, 侯惠莲, 张月浪. 原发性肝平滑肌肉瘤临床病理特征及疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 357-362.
阅读次数
全文


摘要